Michael C. Cameron, MD: Reflecting on Real-World Abrocitinib; An investigator argues for greater prescriber understanding and communication of real-world efficacy and safety outcomes for the latest oral JAK inhibitor approved for atopic dermatitis.

Press/Media

Period13 Jun 2023

Media coverage

2

Media coverage